To validate this molecular crosstalk in a different tumor type driven by KRAS mutations and to verify whether the HIPK2/KRAS cooperation has a causal role in in vivo tumorigenicity, we chose PDAC, the prototype of oncogenic KRAS-driven cancers. Here, HIPK2 is linked to neoplasm.